ArticleScientific reports2021
Comparison between male and female breast cancer survival using propensity score matching analysis.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- The mechanisms and therapeutic advances of interactions between breast cancer and cardiovascular diseases.Frontiers in pharmacology · 2026Review
- Article
- Risks of cataract surgery in solid and hematologic cancer survivors.Scientific reports · 2025Article
- Clinical Characteristics and Survival Trends of Male Breast Cancer in the United States: A Propensity Score Matched Analysis.Journal of personalized medicine · 2025Article
- Comparative Net Survival Analysis of Men and Women With Breast Cancer in Japan: A Population-Based Study.Cancer science · 2025Article
- Survival Rate of Breast Cancer and Related Factors in Iran: A 27-Year Follow-Up.Iranian journal of public health · 2025Article
- Impact of adding preoperative magnetic resonance imaging to ultrasonography on male breast cancer survival: a matched analysis with female breast cancer.Ultrasonography (Seoul, Korea) · 2025Article
- Spontaneous Regression (SR) of Male Breast Cancer (MBC): A Rare Case Highlighting Diagnostic Pitfalls and Management Caution.Case reports in surgery · 2025Article
- Male Breast Cancer: Epidemiology, Diagnosis, Molecular Mechanisms, Therapeutics, and Future Prospective.Oncology research · 2025Review
- Male Breast Cancer: Evaluating the Current Landscape of Diagnosis and Treatment.Breast cancer (Dove Medical Press) · 2025Review
- Elucidating Sex-Specific Immune Profiles in a Breast Cancer Model.International journal of molecular sciences · 2024Article
- Mortality Prediction Modeling for Patients with Breast Cancer Based on Explainable Machine Learning.Cancers · 2024Article
- Unveiling the comorbidity burden of male breast cancer.Scientific reports · 2024Observational
- Male breast cancer: a 32-year retrospective analysis in radiation therapy referral center in northern Iran.Annals of medicine and surgery (2012) · 2024Article
- Article
- Biological Basis of Breast Cancer-Related Disparities in Precision Oncology Era.International journal of molecular sciences · 2024Review
- Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study.Current oncology (Toronto, Ont.) · 2023Article
- Article
- Breast cancer: the first comparative evaluation of oncobiome composition between males and females.Biology of sex differences · 2023Article
- The prediction of distant metastasis risk for male breast cancer patients based on an interpretable machine learning model.BMC medical informatics and decision making · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male breast cancer (MBC) is a rare disease. The few studies on MBC reported conflicting data regarding survival outcomes compared to women. This study has two objectives: to describe the characteristics of a single-cohort of MBC and to compare overall survival (OS) and disease-free survival (DFS) between men and women using the propensity score matching (PSM) analysis. We considered MBC patients (n = 40) diagnosed between January 2004 and May 2019. Clinical, pathological, oncological and follow-up data were analyzed. Univariate analysis was performed to determine the prognostic factors on OS and DFS for MBC. We selected female patients with BC (n = 2678). To minimize the effect of the imbalance of the prognostic factors between the two cohorts, the PSM method (1:3 ratio) was applied and differences in survival between the two groups were assessed. The average age of MBC patients was 73 years. The 5-year OS and DFS rates were 76.7% and 72.2% respectively. The prognostic factors that significantly influenced OS and DFS were tumor size and lymph node status. After the PSM, 5 year-OS was similar between MBC and FBC (72.9% vs 72.3%, p = 0.70) while we found a worse DFS for MBC (72.2% vs 91.4%, p = 0.03). Our data confirmed previous reported MBC characteristics: we found a higher risk of recurrence in MBC compared to FMC but similar OS. MBC and FMC are different entities and studies are needed to understand its epidemiology and guide its management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.